APO-LISINOPRIL TABLET

Land: Canada

Språk: engelsk

Kilde: Health Canada

Aktiv ingrediens:

LISINOPRIL

Tilgjengelig fra:

APOTEX INC

ATC-kode:

C09AA03

INN (International Name):

LISINOPRIL

Dosering :

5MG

Legemiddelform:

TABLET

Sammensetning:

LISINOPRIL 5MG

Administreringsrute:

ORAL

Enheter i pakken:

100/500

Resept typen:

Prescription

Terapeutisk område:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Produkt oppsummering:

Active ingredient group (AIG) number: 0121550003; AHFS:

Autorisasjon status:

APPROVED

Autorisasjon dato:

2001-10-04

Preparatomtale

1 | P a g e
1
PRODUCT MONOGRAPH
PR
APO-LISINOPRIL
(LISINOPRIL TABLETS USP)
TABLETS 5 MG, 10 MG AND 20 MG
ANGIOTENSIN CONVERTING ENZYME INHIBITOR
APOTEX INC.
150 SIGNET DRIVE
TORONTO, ONTARIO
DATE OF REVISION:
M9L 1T9 JANUARY 6, 2022
_Submission Control No.: 255016_
2 | P a g e
PRODUCT MONOGRAPH
Pr
APO-LISINOPRIL
(Lisinopril Tablets USP)
Tablets 5 mg, 10 mg and 20 mg
Angiotensin Converting Enzyme Inhibitor
ACTIONS AND CLINICAL PHARMACOLOGY
Lisinopril is an angiotensin converting enzyme (ACE) inhibitor which
is used in the treatment of
hypertension, congestive heart failure and following myocardial
infarction in hemodynamically
stable patients.
ACE is a peptidyl dipeptidase which catalyzes the conversion of
angiotensin I to the pressor
substance, angiotensin II. Inhibition of ACE results in decreased
plasma angiotensin II, which
leads to increased plasma renin activity (due to removal of negative
feedback of renin release)
and decreased aldosterone secretion. Although the latter decrease is
small, it results in a small
increase in serum potassium. In patients treated with lisinopril and a
thiazide diuretic there was
essentially no change in serum potassium (see PRECAUTIONS).
ACE is identical to kininase II. Thus, lisinopril may also block the
degradation of bradykinin, a
potent vasodilator peptide. However, the role that this plays in the
therapeutic effects of lisinopril
is unknown.
While the mechanism through which lisinopril lowers blood pressure is
believed to be primarily
the suppression of the renin-angiotensin-aldosterone system (RAAS),
lisinopril also lowers blood
pressure in patients with low-renin hypertension.
PHARMACODYNAMICS
Hypertension
_Adults:_ Administration of lisinopril to patients with hypertension
results in a reduction of both
supine and standing blood pressure. Abrupt withdrawal of lisinopril
has not been associated with
a rapid increase in blood pressure. In most patients studied, after
oral administration of an
individual dose of lisinopril, the onset of antihypertensive activity
is seen at